Press

Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds

Apr 26 • 3 min read

Mindset Pharma Inc. (CSE: MSET / FSE: 9DF / OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (“PCT”) for the protection of certain of Mindset’s non-hallucinogenic…

Moon Equity Holdings to Sell BitGift Asset to Silo Wellness in Exchange for a Dividend

Apr 26 • 4 min read

Moon Equity Holdings Corp (OTC: MONI) has signed a binding letter of intent (“LOI”) to divest its BitGift asset to Silo Wellness Inc. ( CSE: SILO / OTCQB: SILFF / FSE: 3K7A), an Oregon-based psychedelics company, for a sum up to CAD$500,000. At closing, MONI plans to allocate the Silo shares as a dividend to…

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

Apr 25 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will host a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference being held on April 25-26 at the Metro Toronto…

Filament Health Announces Spring 2023 Event and Media Appearances

Apr 25 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced upcoming event appearances and media coverage for Spring 2023. EVENTS MEDIA VIRTUAL INVESTOR UPDATE ABOUT FILAMENT HEALTH Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can…

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

Apr 25 • 3 min read

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience in Ottawa, Canada, will present on the anti-depressant and anti-anxiety activity of BetterLife’s 2-bromo-LSD (“BETR-001”) at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435